In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

Jim Cramer, the host of Mad Money, reflected on the uncertainty surrounding the year 2025, focusing on several macroeconomic ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Some investors believe you make money when you buy a stock, not when you sell it ... provided there are good reasons to ...

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

Shares of CRISPR Therapeutics CRSP have lost more than ... sector’s downturn have left investors confused about whether to buy, hold, or sell the stock. Let’s delve into the company’s ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.

CRISPR Therapeutics and Vertex Pharmaceuticals ... You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Just Released: Zacks Top 10 Stocks for 2025 Hurry – you ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

CRISPR Therapeutics' lone approved product has ... Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right ...